Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: Seeking Alpha
SGMT's cash position remains robust at $125.5 million, supporting clinical milestones into 2026 despite ongoing R&D-driven losses and disciplined operating spend. Denifanstat advances in Phase 1 combination studies for MASH and acne, with key data readouts expected in 2026 to drive further stock upside. While early-stage biotech risks persist, SGMT's modest valuation, strong cash runway, and upcoming clinical catalysts offer potential for continued share appreciation. Charday Penn/iStock via Getty Images Thesis Sagimet Biosciences Inc. ( SGMT reported GAAP EPS loss of -$0.40 for 3Q25, which missed most analyst expectations by $0.01. The company also recorded a net loss of $12.91 million for the quarter. The market reaction wasn't too forgiving, with This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote thi
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewswire
- Sagimet Biosciences (NASDAQ:SGMT) had its price target raised by analysts at Citizens Jmp from $33.00 to $35.00. They now have a "market outperform" rating on the stock.MarketBeat
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/14/25 - Form SCHEDULE
- SGMT's page on the SEC website